The findings here provide a mechanistic rationale for hypothesis-driven clinical studies for patients with solid carcinomas treated with class I HDAC inhibitors followed by or in combination with immunotherapy, particularly therapeutic cancer vaccines, where reversal of a tumor immune evasion signature into a more indolent, slower growing, tumor phenotype may translate to heightened clinical benefit [41, 42]. Here, HDAC9 is linked to neoplasm.